← FDA DRUG APPROVALS

FDA BLA · BLA761473

NUFYMCO

ranibizumab-leyk

Sponsor: FORMYCON AG

APPLICATION
BLA761473
TYPE
BLA
ORIGINAL APPROVAL
2025-12-18
LATEST ACTION
2025-12-18
ROUTE
INTRAVITREAL
DOSAGE FORM
INJECTION
MARKETING STATUS
Prescription

Products

NUFYMCOPrescription
RANIBIZUMAB-LEYK 6MG/ML · INJECTION
NUFYMCOPrescription
RANIBIZUMAB-LEYK 10MG/ML · INJECTION

Approval history

2025-12-18Type 2 - New Active Ingredient · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Biologics industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →